The first treatment for Duchenne muscular dystrophy (DMD) has been approved in Canada. Santhera Pharmaceuticals announced that Health Canada approved the company’s Agamree (vamorolone) therapy for DMD in patients four years and older. DMD is a rare inherited X-chromosome-linked disease primarily affecting males. It is characterised by inflammation which is present at birth or shortly […]